Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial

Table 5

The CGM profile of the three groups.

Group	1	2	3
MG
Baseline				0.70
Endpoint				0.00
Δ				0.00
SD
Baseline				0.30
Endpoint				0.01
Δ				0.01
CV%
Baseline				0.35
Endpoint				0.23
Δ				0.17
MAGE
Baseline				0.22
Endpoint				0.26
Δ				0.04
AUC
Baseline	183.3 (60.7, 441.7)	327.2 (115.4, 694.6)	212.6 (64.8, 502.9)	0.63
Endpoint	104.1 (17.7, 204.1)	19.7 (0, 120.0)	128.8 (31.1, 401.0)	0.02
Δ	102.7 (-45.7, 282.5)	229.4 (98.6, 502.7)	26.41 (-110.3, 349.9)	0.01
AOC
Baseline	0 (0, 0)	0 (0, 0)	0 (0, 0)	0.58
Endpoint	0 (0, 0)	0 (0, 0)	0 (0, 0)	0.44
Δ	0 (0, 0)	0 (0, 0)	0 (0, 0)	0.49

Δ: baseline value-endpoint value; : baseline vs. endpoint ; MG: the 24 hrs mean glucose concentration (mmol/L); SD: the 24 hrs standard deviation of the MG (mmol/L); CV%: coefficient of variation (%); MAGE: the 24 hrs mean amplitude of glycaemic excursion (mmol/L); AUC: the incremental area under the  mmol/L (mmol/Lday); AOC: the incremental area over the  mmol/L (mmol/Lday).